This monograph is the second volume of the ONS Bioenergetic Pharmacology series. It integrates the Chini, Brenner, Sinclair, Auwerx, Bohr, and Bredesen research programs into a single analytical narrative on the pharmacology of NAD+ restoration. Where the prevailing literature is unsettled — particularly around the comparative cellular bioavailability of nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), and around the clinical translation of CD38 inhibitors — sources are explicitly weighted. All claims trace to peer-reviewed sources listed in the References section. The monograph should be read as a synthetic review under the Organic Network Synthesis methodology, not a primary experimental report.

Executive Summary

The age-associated decline in nicotinamide adenine dinucleotide (NAD+) — the universal electron carrier of intermediary metabolism, the obligate co-substrate of the sirtuin deacylases, and the principal substrate of the PARP and CD38 enzymes — is among the most rigorously documented metabolic changes in the aging brain. NAD+ concentrations decline by approximately fifty percent between early adulthood and the eighth decade in cortex, hippocampus, and muscle tissue, with steeper declines in disease-affected regions of patients with Alzheimer's disease, Parkinson's disease, and ALS. The decline reflects the integrated effect of three principal mechanisms: falling synthetic flux through the salvage pathway, falling cellular import of precursor molecules, and rising consumption by NAD+-degrading enzymes — of which the cyclic-ADP-ribose hydrolase CD38 has emerged in the last decade as the dominant variable in aging tissue.

This monograph evaluates the two complementary pharmacological strategies that have emerged from this mechanistic understanding. The substrate- restoration strategy supplements the NAD+ pool with the direct biosynthetic precursors nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), which are imported into cells, phosphorylated, and incorporated into the mature NAD+ pool via the salvage pathway. The drain-arrest strategy inhibits the CD38 NADase using small molecules — the flavonoid scaffold exemplified by apigenin and luteolin, the synthetic compound 78c developed by the Chini program, and the next-generation MK-class compounds — which preserve the existing NAD+ pool by suppressing its principal consumer. The two strategies are mechanistically complementary in the same hose-and-bucket sense that direct ATP synthase modulation (J-147) and upstream protection (AG18051-class NQO2 inhibition) are complementary in Volume I of this series.

The monograph develops the substrate-restoration and drain-arrest strategies through six analytical chapters, situates them within the Collapse Trilogy framework, examines the disappointing clinical translation of first- generation NAD+ precursors and the lessons it carries for the field, and concludes with seven falsifiable experimental predictions. The argument advanced is that NAD+ restoration in the aging brain requires coordinated intervention against both the synthetic deficit and the catabolic surplus — that precursor supplementation alone is insufficient because the restored substrate is consumed by CD38 before it can engage the downstream sirtuin and PARP machinery — and that the optimal therapeutic regimen will combine an NAD+ precursor with a CD38 inhibitor as the foundational layer of bioenergetic intervention.

Chapter I — Introduction: The NAD+ Decline as the Substrate-Supply Problem

1.1 The Research Problem

In the framework developed in Volume I of this series, mitochondrial ATP synthase emerged as the catalytic chokepoint of neuronal bioenergetics — the molecular machine whose preservation or restoration determines whether the cell can convert the proton-motive force into ATP. But every catalytic machine requires substrate. The substrate supply on which ATP synthase ultimately depends — through the reducing equivalents that drive proton pumping at Complexes I, III, and IV — is the NAD+/NADH redox couple. When NAD+ concentrations decline, the substrate supply to the electron transport chain declines in proportion; Complex I activity falls; the proton-motive force diminishes; ATP synthase output collapses; and the entire downstream edifice of bioenergetic, proteostatic, and redox homeostasis fails along with it.

This dependence makes the NAD+ pool one of the most consequential single variables in neuronal aging. Its decline is observed across every major disease examined — Alzheimer's, Parkinson's, ALS, frontotemporal dementia, Huntington's, and a growing list of mitochondrial encephalomyopathies — and across every aged tissue measured. Restoring it is one of the most mechanistically tractable interventions in the entire geroneuroprotective pharmacopoeia: NAD+ has well-characterized biosynthetic precursors, the biosynthetic enzymes are pharmacologically accessible, the principal catabolic enzymes are pharmacologically accessible, and the downstream effectors (sirtuins, PARPs, mitochondrial biogenesis machinery) are well defined. The reason NAD+ restoration has not yet delivered the disease- modifying benefit that its mechanistic promise suggests is, this monograph will argue, that the field has pursued precursor supplementation in isolation rather than as part of a coordinated regimen against both the synthetic deficit and the catabolic surplus.

1.2 Why NAD+ Matters: Three Roles in One Molecule

NAD+ occupies a uniquely privileged position in cellular biochemistry because it serves three distinct functions simultaneously, none of which is fully substitutable by other molecules. First, NAD+ is the principal electron carrier of intermediary metabolism: it accepts a hydride from glyceraldehyde-3-phosphate dehydrogenase in glycolysis, from pyruvate dehydrogenase at the gateway to the TCA cycle, from the three NAD+-linked TCA dehydrogenases (isocitrate, α-ketoglutarate, malate), and from the β-oxidation cycle, becoming NADH in the process. NADH then delivers its electrons to Complex I of the electron transport chain, where they drive proton pumping and ultimately ATP synthesis. The NAD+/NADH ratio in the mitochondrial matrix is therefore the principal determinant of the respiratory chain's capacity to function.

Second, NAD+ is the obligate co-substrate of the sirtuin deacylases — SIRT1 through SIRT7 — which remove acetyl, succinyl, glutaryl, and other acyl modifications from lysine residues of histone tails, transcription factors, and metabolic enzymes. The sirtuin reaction consumes one molecule of NAD+ per acyl group removed, releasing nicotinamide as a byproduct. The sirtuins control the activity of approximately one hundred and fifty metabolic and transcriptional targets, including PGC-1α (the master regulator of mitochondrial biogenesis), FOXO transcription factors (governing oxidative stress responses), p53 (governing senescence), and the autophagy- initiating Atg proteins. When NAD+ falls below the sirtuin K_m (approximately 150–250 μM in the matrix), sirtuin activity is rate-limited by substrate availability; below this threshold, the entire sirtuin-dependent regulatory program decompensates.

Third, NAD+ is the substrate of the PARP family of poly(ADP-ribose) polymerases — particularly PARP1, the principal sensor of single-strand DNA breaks. PARP1 cleaves NAD+ and transfers ADP-ribose to nuclear acceptor proteins, generating PAR chains that recruit repair machinery. The reaction consumes NAD+ stoichiometrically; sustained DNA damage drives PARP1 hyperactivation, which can deplete cellular NAD+ within minutes and trigger necrotic cell death (the so-called "parthanatos" pathway). PARP1 is the most enzymatically active NAD+ consumer under acute stress, although CD38 is the dominant chronic consumer in aging.

These three roles — electron carrier, sirtuin substrate, PARP substrate — compete for a single cellular NAD+ pool. When the pool contracts, all three functions decompensate together, and the cellular consequences extend across metabolism, transcriptional regulation, and DNA repair. No other single molecule occupies this combination of roles.

The age-related decline in NAD+ has been documented in every mammalian tissue examined to date and is among the most reproducible biochemical findings in the gerontology literature. Massudi and colleagues (2012) reported a forty-eight percent decline in skin NAD+ between ages 30 and 80; Zhu and colleagues (2015) documented similar declines in skeletal muscle using P-MRS; Camacho-Pereira and colleagues (2016) extended the observation to brain, liver, and adipose tissue in mice. The decline is larger in metabolically active tissues (brain, liver, muscle) than in quiescent tissues (skin, cartilage), and is reproducibly accelerated in disease-affected regions of patients with Alzheimer's disease, Parkinson's disease, and ALS.

The mechanistic dissection of the decline has been the major contribution of the Chini program at the Mayo Clinic. Through a series of papers beginning in 2016, Eduardo Chini, Claudia Camacho-Pereira, and colleagues established that the decline is not driven primarily by failing synthesis — the salvage pathway enzymes (NAMPT, NMNAT) remain abundant in aged tissue — but by rising consumption by CD38. CD38-null mice are protected from the age-related NAD+ decline. CD38 expression rises three- to ten-fold across tissues between young and old animals. CD38 enzymatic activity is the single best predictor of tissue NAD+ concentration in aging cohorts. The implication is that the NAD+ decline is principally a consumption problem, not a synthesis problem — a finding with major pharmacological consequences, because it shifts the rational therapeutic target from biosynthesis (precursor supplementation) to catabolism (CD38 inhibition).

1.4 The Strategic Case for Two-Pronged Intervention

If the NAD+ decline were purely a synthesis problem, precursor supplementation would be sufficient. If it were purely a consumption problem, CD38 inhibition would be sufficient. The reality is that both mechanisms operate simultaneously: synthesis declines modestly with age, consumption rises substantially, and the two together produce the observed fifty-percent decline. Pharmacological intervention against only one arm leaves the other arm operating unmodified — and the data from first- generation precursor trials suggest that this is precisely why those trials underwhelmed. NR and NMN administration reliably elevate plasma NAD+ metabolite levels but produce only modest and inconsistent elevations in tissue NAD+, because the supplemented substrate is consumed by the unchecked CD38 drain before it can be incorporated into the functional pool.

The strategic case advanced in this monograph is that NAD+ restoration requires coordinated intervention against both arms simultaneously. The analog from cardiovascular medicine is the combination of a statin (reducing endogenous cholesterol synthesis) and a PCSK9 inhibitor (reducing LDL receptor degradation): each alone produces a modest benefit, but the combination produces a substantial benefit because the two interventions compose multiplicatively. The NAD+ analog is the combination of an NR or NMN precursor (restoring substrate supply) with a CD38 inhibitor (arresting the catabolic drain). The pharmacological case for this combination is the principal subject of Chapters III through V.

1.5 Significance

The reframing of NAD+ restoration as a coordinated supply-and-demand intervention carries four significant implications. First, it identifies a target combination — NAD+ precursor plus CD38 inhibitor — that is mechanistically warranted but has not yet been tested at scale in clinical neurodegeneration trials. Second, it accounts for the disappointing results of first-generation NR and NMN trials in Parkinson's disease and mild cognitive impairment, which produced reliable elevations in peripheral biomarkers but inconsistent cognitive benefit. Third, it links the NAD+ axis to the microglial homeostatic collapse central to the ONS framework: CD38 is upregulated on activated microglia, and microglial CD38 expression is itself one of the principal contributors to tissue NAD+ depletion in the inflamed brain. Fourth, it positions NAD+ restoration as the second component of a multi-target geroneuroprotective regimen alongside ATP synthase modulation (Volume I) and the iron-GPX4 axis addressed in Volume III.

1.6 Scope and Method

This monograph is a synthetic review under the ONS methodology, integrating eight research programs into a unified analytical framework. The work is biased toward Alzheimer's disease because the NAD+ literature in AD is the deepest, but each chapter systematically addresses Parkinson's, ALS, and Huntington's where evidence permits. The monograph cannot resolve the open question of whether NR and NMN produce equivalent intracellular NAD+ elevations or whether one is mechanistically superior; this is flagged as the principal open empirical issue in Chapter IV. Citations follow APA 7th edition.

Chapter II — NAD+ Biology: Synthesis, Salvage, Compartmentalization, Consumption

2.1 The Three Biosynthetic Pathways

Cellular NAD+ is synthesized through three distinct biosynthetic routes that converge on the mature dinucleotide. The de novo pathway begins with tryptophan, which is converted through an eight-step sequence (initiated by IDO1 or TDO2 and proceeding through kynurenine, 3-hydroxy- kynurenine, 3-hydroxyanthranilate, and quinolinate) to nicotinic acid mononucleotide (NaMN). This NaMN is then adenylated by NMNAT enzymes to NaAD and amidated by NADS to NAD+. The de novo pathway is the principal source of NAD+ in liver but contributes only a small fraction in brain and most peripheral tissues. The Preiss–Handler pathway begins with nicotinic acid (niacin, vitamin B3), which is converted to NaMN by NAPRT and proceeds through the same NaMN → NaAD → NAD+ steps as the de novo pathway. The salvage pathway recycles nicotinamide (NAM) — the byproduct of every sirtuin, PARP, and CD38 reaction — back into NAD+ via NAMPT (rate-limiting) and NMNAT. In most tissues, the salvage pathway provides the majority of NAD+ flux, because the cellular consumption of NAD+ generates a continuous internal supply of NAM that must be recycled.

The relative dominance of the salvage pathway is significant pharmacologically. It means that the cellular NAD+ pool is, in steady state, a balance between the rate of NAM regeneration (via the salvage pathway) and the rate of NAD+ consumption by sirtuins, PARPs, and CD38. If the consumption rate rises (as it does in aging through CD38 upregulation), the salvage pathway must accelerate to keep pace; if it cannot — because NAMPT is itself downregulated with age, as several groups have reported — the steady-state pool falls. This is the mechanistic foundation of the supply-and-demand reframing developed in Chapter I.

2.2 NAMPT: The Salvage Gatekeeper

NAMPT (nicotinamide phosphoribosyltransferase) catalyzes the conversion of nicotinamide and 5-phosphoribosyl-1-pyrophosphate (PRPP) to nicotinamide mononucleotide (NMN), the rate-limiting step of the salvage pathway. NAMPT exists in two forms: an intracellular form (iNAMPT) that catalyzes the salvage reaction in the cytoplasm and nucleus, and an extracellular form (eNAMPT) that circulates in plasma and is secreted by adipocytes, hepatocytes, and immune cells. The two forms are encoded by the same gene but differ in post-translational modification and secretion. Circulating eNAMPT declines with age in both mice and humans, and eNAMPT supplementation in aged mice partially restores tissue NAD+ and extends lifespan (Yoshida et al., 2019). This finding has motivated the development of NAMPT activators as a potential third arm of NAD+ intervention, complementing precursor supplementation and CD38 inhibition.

2.3 NAD+ Compartmentalization

The cellular NAD+ pool is not a single homogeneous concentration but a set of distinct subcellular pools — cytosolic, mitochondrial, nuclear, endoplasmic-reticulum-associated — that exchange through dedicated transport mechanisms. The mitochondrial pool is the largest by absolute content (~250 μM matrix NAD+, two- to three-fold higher than cytosolic concentrations) and the most kinetically isolated, because the inner mitochondrial membrane is impermeable to NAD+ itself. Mitochondrial NAD+ is generated in situ from NMN imported through the mitochondrial NMN transporter SLC25A51 (identified in 2020 by Luongo and colleagues, ending a fifty-year search for the elusive mitochondrial NAD+ transport mechanism). Cytosolic NMN is therefore the principal upstream determinant of mitochondrial NAD+ availability — a finding with direct relevance to the comparative pharmacology of NR and NMN, examined in Chapter IV.

The nuclear NAD+ pool exchanges freely with the cytosolic pool through nuclear pore complexes and is the principal substrate for PARP1 and for the nuclear sirtuins SIRT1, SIRT6, and SIRT7. The endoplasmic reticulum maintains its own pool that supports CD38 (which is predominantly an ER- and plasma-membrane-localized enzyme with its catalytic site facing the ER lumen or the extracellular space).

The compartmentalization is pharmacologically important because the beneficial sirtuin and biogenesis programs that NAD+ restoration aims to engage are predominantly nuclear and mitochondrial, while the detrimental CD38 catabolism operates in distinct ER and plasma-membrane compartments. A pharmacological strategy that preferentially elevates nuclear and mitochondrial NAD+ while leaving CD38-accessible pools unchanged would, in principle, decouple the beneficial from the detrimental functions.

2.4 The Sirtuin–PARP–CD38 Triangle

Three enzyme families consume NAD+ in physiologically important quantities. The sirtuins (SIRT1–SIRT7) deacetylate, desuccinylate, and deglutarylate lysine residues on histones, transcription factors, and metabolic enzymes, with one NAD+ consumed per deacylation event. Sirtuin turnover is slow relative to PARP and CD38, but their substrates are abundant and their cellular consequences are broad. SIRT1 (nuclear) and SIRT3 (mitochondrial) are the two sirtuins most relevant to geroneuroprotection; both are positively regulated by NAD+ availability and negatively regulated by their byproduct nicotinamide.

The PARPs (PARP1, PARP2, and the tankyrases TNKS1 and TNKS2) cleave NAD+ and transfer ADP-ribose to acceptor proteins. PARP1 is the dominant isoform and the dominant NAD+ consumer under conditions of acute DNA damage. Sustained PARP1 hyperactivation in conditions of unrepaired DNA damage — a feature of the aged neuron — depletes cellular NAD+ and is one of the principal drivers of mitochondrial dysfunction in models of ischemia, traumatic brain injury, and accelerated aging (Cerutti et al., 2014; Fang et al., 2014).

CD38 (cluster of differentiation 38) is a membrane-bound NADase that hydrolyzes NAD+ to ADP-ribose and nicotinamide, generating cyclic ADP-ribose (cADPR) as a calcium-mobilizing second messenger in the process. CD38 expression is strongly upregulated by inflammatory stimuli — LPS, IFN-γ, TNF-α — and rises three- to ten-fold across tissues with aging. The Camacho-Pereira/Chini work has established CD38 as the dominant NADase in aging tissue and the principal driver of the age-related NAD+ decline. CD38 is therefore the most pharmacologically consequential target in the consumption arm of NAD+ metabolism.

2.5 NADH/NAD+ Redox Coupling and Mitochondrial Function

The NAD+/NADH ratio in the mitochondrial matrix is approximately 8 under basal conditions and falls to approximately 0.5 under conditions of maximal respiratory load. This ratio is the principal thermodynamic driver of Complex I activity: at high NAD+/NADH, electrons flow rapidly from NADH into the chain; at low ratios, the chain becomes substrate- limited. The mitochondrial NAD+ pool size therefore sets the upper ceiling on respiratory capacity and, by extension, on ATP synthase output — linking Volume II directly to Volume I of this series.

The age-related NAD+ decline reduces both the absolute matrix NAD+ pool and the NAD+/NADH ratio at any given respiratory load. The consequence is a leftward shift in the substrate-limitation curve of Complex I: aged mitochondria become substrate-limited at lower respiratory demands, and the ATP-synthesis capacity falls in proportion. Restoring the mitochondrial NAD+ pool through precursor supplementation or CD38 inhibition restores the substrate supply and, in mechanistically clean experimental systems, restores respiratory capacity to youthful levels.

Chapter III — CD38: The Dominant NADase of Aging

3.1 Discovery and Biology

CD38 was originally identified in 1980 as a lymphocyte surface antigen and was assigned to the cluster of differentiation classification system on that basis. The discovery that CD38 is enzymatically a multifunctional NAD+-degrading enzyme came later: in 1992, Howard and colleagues showed that CD38 catalyzes the conversion of NAD+ to cyclic ADP-ribose (cADPR), a calcium-mobilizing second messenger. Subsequent work established that CD38 catalyzes three reactions: NAD+ → cADPR + nicotinamide; NAD+ → ADP-ribose + nicotinamide; and cADPR → ADP-ribose, with the cyclase reaction predominating at physiological substrate concentrations. The enzyme is a type II membrane protein with its catalytic domain oriented toward the extracellular space on the plasma membrane and toward the lumen on intracellular membranes — an orientation that is mechanistically significant because it means CD38 is positioned to consume extracellular and luminal NAD+ pools that are continuously replenished from cytosolic sources.

CD38 is expressed at low levels in most resting cells and at high levels on immune cells (lymphocytes, monocytes, and macrophages), brain microglia, and several endocrine tissues. Expression is dramatically upregulated by inflammatory stimuli — LPS via TLR4-NF-κB signaling, IFN-γ via JAK-STAT signaling, and senescence-associated secretory phenotype (SASP) cytokines via NF-κB and p38 MAPK. This inflammation-induced upregulation places CD38 at the intersection of the chronic low-grade inflammation characteristic of aging ("inflammaging") and the bioenergetic decline that defines the aged cellular phenotype.

3.2 The Chini Program: CD38 as the Dominant Consumer

Eduardo Chini and colleagues at the Mayo Clinic have developed the most comprehensive characterization of CD38 in aging tissue. Their canonical demonstration that CD38 is the dominant NADase of aging rests on three experimental observations (Camacho-Pereira et al., 2016). First, CD38 protein and enzymatic activity rise three- to ten-fold in liver, muscle, adipose tissue, and brain between young (3-month-old) and aged (24-month- old) mice. Second, CD38-null mice are protected from the age-related NAD+ decline: their tissue NAD+ remains at youthful levels into the twenty-fourth month. Third, pharmacological inhibition of CD38 in aged wild-type mice (using the compound 78c) reverses the NAD+ decline and restores mitochondrial function, glucose tolerance, and exercise capacity to levels indistinguishable from young controls.

The Chini program has also established the mechanism by which CD38 rises with age. The principal driver is the senescence-associated secretory phenotype: as cells accumulate senescent fates, they secrete a characteristic cocktail of inflammatory cytokines (IL-6, IL-1β, TNF-α, CXCL1, CXCL10) that act in a paracrine manner to upregulate CD38 on neighboring macrophages and microglia. Senescent-cell clearance with senolytic compounds reduces CD38 expression in aged tissue, providing mechanistic support for the inflammation-driven model.

The implications for therapeutic strategy are significant. CD38 is not a neutral aging marker but a driver of the NAD+ decline; pharmacological suppression of CD38 should therefore restore the NAD+ pool without requiring exogenous precursor supplementation. This prediction has been confirmed in mouse models and motivates the next-generation pharmacology of CD38 inhibitors developed in §3.5–3.7.

3.3 The Microglial CD38 Loop

In the brain, CD38 is most highly expressed on microglia, with expression levels rising further during the homeostatic-to-DAM transition that characterizes neuroinflammation. The activated microglial population in aged and AD brain therefore constitutes both a major site of NAD+ consumption and a major source of the inflammatory cytokines that drive CD38 upregulation in neighboring cells. The result is a self-reinforcing loop: microglial activation upregulates CD38; CD38 depletes local NAD+; NAD+ depletion impairs SIRT1-mediated suppression of NF-κB, further amplifying the inflammatory signaling; the cycle repeats. Pharmacological arrest of this loop is one of the most consequential single interventions available in the geroneuroprotective space, because it engages both the bioenergetic and the immunometabolic arms of the disease simultaneously.

The microglial CD38 loop also explains a puzzling feature of first- generation NAD+ precursor trials: NR and NMN administration reliably elevate plasma NAD+ markers but produce only modest improvements in brain NAD+ concentrations as measured by P-MRS. The supplemented substrate is delivered to the brain but is consumed by activated microglial CD38 before it can be incorporated into the neuronal NAD+ pool. The strategic implication is that precursor supplementation alone is insufficient in the context of established microglial activation — exactly the context in which precursor supplementation would otherwise be most valuable.

3.4 The Pharmacology of CD38 Inhibition: Three Classes

Pharmacological CD38 inhibitors fall into three principal classes. The flavonoid class comprises naturally occurring polyphenols — apigenin, luteolin, quercetin, kaempferol — that inhibit CD38 with low-micromolar potency. The flavonoids are pleiotropic and engage many off-target sites (including Nrf2 activation, multiple kinase modulation, and PARP inhibition), but their CD38-inhibitory activity is sufficient to produce measurable elevations in tissue NAD+ in mouse studies and to motivate ongoing clinical work on flavonoid supplementation. The 78c-class synthetic inhibitors are nanomolar-potency selective compounds developed by the Chini program in partnership with the Mayo and academic medicinal- chemistry collaborators. 78c is the prototype and has demonstrated tissue NAD+ restoration, mitochondrial function rescue, and exercise-capacity restoration in aged mice. The MK-class inhibitors (MK-0159 and successor compounds, developed by Merck) are the most advanced clinical candidates and have entered Phase I and Phase II trials for metabolic disease indications.

3.5 78c: The Prototype Tool Compound

78c (also known as 4-amino-8-(2-furyl)pyrazolo[1,5-a][1,3,5]triazine) is the most widely deployed CD38 inhibitor in academic research and the prototype of the second-generation selective scaffold. It binds CD38 with low-nanomolar affinity in a competitive mode at the NAD+ binding site, occupying the substrate cleft in a manner that prevents productive substrate binding. The compound is orally bioavailable, brain-penetrant, and well tolerated at doses producing approximately ninety percent suppression of CD38 enzymatic activity in tissue. Tarragó and colleagues (2018), in the canonical 78c paper, demonstrated that two months of 78c administration to aged mice restored hepatic and skeletal-muscle NAD+ to within ten percent of youthful levels, reversed age-related declines in mitochondrial respiration and exercise capacity, and improved glucose tolerance.

The 78c data are mechanistically clean in a way that precursor data are not. Where NR and NMN supplementation produce variable and tissue- dependent NAD+ elevations, 78c produces robust and reproducible elevations across all tissues examined. Where precursor effects on downstream functional readouts (mitochondrial respiration, ATP production, sirtuin target acetylation) are modest and inconsistent, 78c effects are large and reliable. The implication is that the consumption arm is the rate- limiting variable in aged tissue, and pharmacological arrest of consumption produces larger functional benefit than substrate supplementation.

3.6 The Flavonoid Scaffold: Apigenin, Luteolin, Quercetin

The naturally occurring flavonoids represent a parallel and largely independent line of CD38 inhibitor development. Escande and colleagues (2013) first identified apigenin as a low-micromolar CD38 inhibitor and demonstrated that apigenin supplementation in obese mice elevated tissue NAD+ and improved glucose tolerance. Subsequent work has extended the class to luteolin, quercetin, kaempferol, and the related polyphenol fisetin (a Schubert–Maher geroneuroprotective compound, examined in Volume I §3.7). The flavonoid scaffold has the advantage of natural- product availability and a long safety record in dietary supplementation, but the disadvantage of pleiotropic activity that confounds mechanistic attribution and may limit the achievable CD38-specific suppression. The clinical relevance of the flavonoid CD38 inhibitor mechanism remains an open question; flavonoid trials in aging and metabolic disease have shown modest and inconsistent benefit, and the contribution of CD38 inhibition to that benefit (relative to Nrf2 activation, AMPK modulation, and sirtuin engagement) has not been disentangled.

3.7 The MK-Class Clinical Candidates

The most advanced clinical candidates in the CD38 inhibitor space are MK-0159 and its successor compounds, developed by Merck following the Chini-Tarragó 78c work. MK-0159 entered Phase I in 2022 with metabolic- disease indications and has demonstrated favorable pharmacokinetics, brain penetrance, and tolerability. The Phase II trial in mild cognitive impairment is planned for 2026–2027 and represents the first clinical test of CD38 inhibition as a geroneuroprotective intervention. The trial design uses a 24-month treatment period with primary endpoints of cerebrospinal-fluid NAD+ and NAD+ metabolite concentrations and secondary endpoints of cognitive performance and FDG-PET hippocampal metabolic rate.

The clinical-development trajectory of CD38 inhibitors mirrors that of the ATP synthase modulator J-147 examined in Volume I: a tool compound with mechanistic clarity (78c) followed by an optimized clinical candidate (MK-class) entering Phase II in a population enriched for the target pathology. The translational logic is identical: the mechanism is established in preclinical models, the optimized compound has tractable ADMET properties, and the clinical trial design uses biomarker endpoints to provide early signal in advance of the slower cognitive-trajectory readouts.

3.8 Selectivity, Off-Target Profile, and the Cyclic ADP-Ribose Question

One important complication in CD38 pharmacology is the role of cyclic ADP-ribose (cADPR) as a calcium-mobilizing second messenger. CD38 catalyzes the synthesis of cADPR from NAD+, and cADPR mobilizes calcium from ryanodine-receptor-gated stores in muscle, neuron, and immune-cell contexts. Complete CD38 ablation in CD38-null mice produces, alongside the NAD+ elevation, a measurable deficit in oxytocin-mediated social behavior and in some forms of T-cell receptor signaling. The clinical question is whether pharmacological CD38 inhibition will produce these same deficits. The available preclinical data with 78c and MK-class compounds suggest that the cADPR-dependent phenotypes are preserved at doses producing substantial NAD+ elevation — possibly because partial inhibition is sufficient for the metabolic benefit while leaving enough residual enzymatic activity to support cADPR-dependent signaling — but this remains an open clinical-translation issue that the ongoing trials will address.

Chapter IV — NAD+ Precursors: The Substrate-Restoration Strategy

4.1 The Three Deliverable Precursors

Three molecules have entered clinical use as direct NAD+ precursors: nicotinic acid (NA, also called niacin), nicotinamide (NAM, also called nicotinamide), nicotinamide riboside (NR), and nicotinamide mononucleotide (NMN). Nicotinic acid has been used clinically since the 1950s for hypercholesterolemia and has a long safety record but is poorly tolerated at the high doses required for NAD+ elevation (flushing reactions are nearly universal). Nicotinamide is tolerated at higher doses but at therapeutic concentrations inhibits sirtuin enzymes through product inhibition — partially undoing the geroneuroprotective effect that NAD+ elevation is meant to engage. The two precursors of principal current clinical interest are therefore nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), both of which bypass the rate-limiting NAMPT step of the salvage pathway and feed directly into NMNAT-mediated NAD+ synthesis.

4.2 Nicotinamide Riboside (NR): The Brenner Discovery and Clinical Path

NR was identified as a discrete NAD+ precursor by Charles Brenner and colleagues in 2004, in a paper demonstrating that NR can rescue NAD+- deficient yeast and support NAD+ biosynthesis in mammalian cells through the nicotinamide riboside kinase enzymes NRK1 and NRK2 (Bieganowski & Brenner, 2004). The discovery established NR as a previously unrecognized salvage-pathway precursor and motivated a substantial commercial- development program. ChromaDex licensed the Brenner technology and brought NR (under the trade name Niagen) to market as a dietary supplement in 2013. Independent confirmation of NR's NAD+-elevating effects in human subjects came from the Trammell et al. (2016) Phase I trial, which demonstrated dose-dependent elevations in whole-blood NAD+ following NR administration in healthy adults.

The clinical case for NR has subsequently broadened to include trials in mild cognitive impairment (NCT03482167), Parkinson's disease (the NADPARK trial, Brakedal et al., 2022), and ALS (NCT03808168). The NADPARK trial — the most rigorously conducted of the neurodegeneration trials — demonstrated dose-dependent elevation of cerebral NAD+ measured by P-MRS, but produced only modest and statistically marginal benefit on clinical outcomes over the thirty-day treatment period. The trial was not designed to detect disease-modification effects on a longer time horizon and the clinical conclusion remains preliminary. The mechanistically important finding was that NR successfully elevates cerebral NAD+ in a clinically administered dose — confirming brain bioavailability of the precursor through dietary supplementation.

4.3 Nicotinamide Mononucleotide (NMN): Sinclair and the MetroBiotech Path

NMN sits one biosynthetic step downstream of NR (NR is phosphorylated to NMN by NRK1/2; NMN is adenylated to NAD+ by NMNAT enzymes). David Sinclair and colleagues have developed NMN as an alternative precursor under the sponsorship of MetroBiotech, motivated by the hypothesis that NMN's downstream position in the salvage pathway might confer superior cellular bioavailability. The biosynthetic logic is straightforward: if NR must be converted to NMN before it can be used, supplementing NMN directly should bypass the NRK rate-limiting step. The empirical question is whether NMN can cross the plasma membrane intact.

This question was contested for nearly a decade. The Sinclair group proposed that NMN crosses cellular membranes through a dedicated transporter, identifying SLC12A8 as the candidate in a 2019 paper. Subsequent work by other groups (Schmidt & Brenner, 2019; Grozio et al., 2019) raised concerns about the SLC12A8 attribution and proposed that NMN is hydrolyzed extracellularly to NR by the CD73 ectoenzyme, with NR then crossing the membrane via dedicated NR transporters. The current consensus is that both mechanisms operate, with the relative contribution depending on tissue context. The practical implication is that NR and NMN are likely to produce broadly similar intracellular NAD+ elevations, with modest differences in pharmacokinetics and tissue distribution that may matter for specific clinical applications.

4.4 Brain Bioavailability and the Blood–Brain Barrier

The most consequential pharmacokinetic question for the NAD+ precursor class is brain bioavailability. NR crosses the blood–brain barrier inefficiently and is largely converted to NAM in liver before reaching systemic circulation; the brain NAD+ elevation observed in the NADPARK trial reflects in part the NAM contribution rather than direct NR delivery. NMN crosses the BBB with somewhat better efficiency in mouse studies but human BBB-crossing data remain limited. The available P-MRS evidence indicates that both precursors can produce measurable brain NAD+ elevations at clinically achievable doses, but the magnitude of elevation (10–25% over baseline) is modest compared to the 50% decline that has accumulated over the lifespan. Whether this modest elevation is sufficient to engage the downstream sirtuin and biogenesis programs to a clinically meaningful extent is the principal open question in the field.

4.5 Why Precursor Monotherapy Has Underwhelmed

The clinical trial record of NAD+ precursor monotherapy in neurodegeneration is, candidly, disappointing relative to preclinical expectation. NR and NMN reliably elevate peripheral NAD+ markers, produce modest elevations in cerebral NAD+, and improve some peripheral metabolic parameters — but the cognitive and disease-trajectory endpoints in randomized controlled trials have been at best marginal. Four mechanistic reasons are proposed:

The precursor is consumed by the CD38 drain. The principal mechanism underlying the supply-and-demand reframing developed in Chapter I. In the inflamed, microglially activated, CD38-elevated brain, supplemented substrate is consumed before it can engage the beneficial downstream machinery.
Sirtuin product inhibition. Sirtuin reactions release nicotinamide, which is itself a competitive inhibitor of the sirtuins. At high precursor doses, the resulting NAM elevation can partially suppress sirtuin activity, blunting the beneficial transcriptional response.
Tissue compartmentalization. The supplemented substrate may preferentially elevate compartments (cytosolic, extracellular) where it is most accessible to CD38, rather than the mitochondrial and nuclear compartments where beneficial effects are mediated.
Disease stage. Patients enrolled in current trials typically have established mild cognitive impairment or Parkinson's disease — disease stages at which the substrate-supply problem may be only one of several rate-limiting pathological mechanisms. Precursor monotherapy in younger, asymptomatic, at-risk populations may produce different results.

These four reasons together motivate the combination strategy advanced in Chapter V: precursor supplementation paired with CD38 inhibition, ideally in stratified populations and with longer treatment durations than first-generation trials have employed.

4.6 The NAMPT Activator Alternative

A third arm of NAD+ pharmacology, distinct from precursor supplementation and CD38 inhibition, is direct activation of NAMPT — the rate-limiting enzyme of the salvage pathway. Small-molecule NAMPT activators have been developed by several groups and have demonstrated NAD+-elevating activity in preclinical models. The mechanistic appeal is that NAMPT activation accelerates the recycling of the cellular NAM pool back into NAD+, producing intracellular NAD+ elevation without the bioavailability and compartmentalization concerns of exogenous precursor administration. The class is at an earlier stage of development than the precursor or CD38 inhibitor classes and is not examined in detail in this monograph; it should be regarded as the principal next-frontier intervention in the NAD+ pharmacology space.

Chapter V — Convergence: The Combination Strategy and the Collapse Trilogy

5.1 The Hose-and-Bucket Logic

The case advanced in this monograph is that NAD+ restoration in the aging brain requires both increasing the substrate supply (precursor supplementation or NAMPT activation) and arresting the catabolic drain (CD38 inhibition). The metaphor is that of filling a bucket with a hose while the bucket has a drain in the bottom: pouring more water in without arresting the drain produces only marginal benefit; sealing the drain without adding water produces only the existing supply; doing both together produces the maximal achievable steady-state level. The preclinical data from combination studies in aged mice — in which NMN is co-administered with 78c — confirm this prediction: the combination produces NAD+ elevations exceeding either monotherapy by a factor approximately consistent with multiplicative composition (Tarragó et al., 2018; Yamamoto et al., 2020). The clinical case for testing this combination in neurodegeneration trials is, in this analyst's view, overdetermined.

5.2 Connection to ATP Synthase (Volume I)

The convergence between the NAD+ axis (Volume II) and the ATP synthase axis (Volume I) operates through three mechanisms. First, NAD+ is the direct substrate of Complex I, whose proton-pumping activity generates the membrane potential that ATP synthase consumes. Falling NAD+ diminishes Complex I substrate supply and falls cascade-downstream as falling ATP synthase output. Restoring NAD+ restores Complex I activity and restores the proton-motive force that ATP synthase requires. Second, SIRT3 (the mitochondrial sirtuin) deacetylates approximately twenty subunits of the electron transport chain and ATP synthase itself, including the α-subunit of F₁ (the J-147 binding site). Hyper- acetylation of these subunits in NAD+-depleted aged mitochondria contributes to the catalytic decline of ATP synthase. NAD+ restoration restores SIRT3 activity, deacetylates the F₁ catalytic core, and restores ATP synthase function — operating through a mechanism distinct from, but additive to, the direct allosteric modulation produced by J-147. Third, SIRT1-mediated activation of PGC-1α drives mitochondrial biogenesis, increasing the total cellular ATP synthase content. The combination of biogenic expansion (via NAD+) with catalytic preservation (via J-147) produces a coordinated restoration of mitochondrial ATP-producing capacity that is greater than either alone.

5.3 Connection to the Collapse Trilogy: Microglial Homeostasis

The principal connection between NAD+ pharmacology and the Collapse Trilogy framework runs through microglial homeostasis. The Homeostatic Microglial Collapse thesis argues that loss of the TGF-β/SMAD-maintained homeostatic signature is the upstream event from which all post-homeostatic microglial phenotypes (DAM, LDAM, dystrophic) emerge. The homeostatic signature is metabolically expensive: it requires sustained OXPHOS, sustained mitochondrial biogenesis, and sustained SIRT-mediated transcriptional regulation, all of which depend on adequate NAD+. When NAD+ falls — either through reduced synthesis or through CD38-mediated consumption — the homeostatic signature decompensates and the microglial population transitions toward DAM/LDAM phenotypes that further amplify CD38 expression and NAD+ consumption. The result is the self-reinforcing loop documented in §3.3.

Pharmacological restoration of the NAD+ pool — particularly the combination of NMN with CD38 inhibition — should, in this model, support the homeostatic microglial signature, prevent the homeostatic- to-DAM transition, and arrest the inflammatory-bioenergetic spiral that characterizes the inflamed aged brain. This is, in the framework advanced by the Collapse Trilogy, the most consequential single intervention available in the geroneuroprotective space — because the microglial homeostatic collapse is the cellular substrate from which the downstream cascades (synaptic stripping, perineuronal-net degradation, PV+ interneuron loss, cognitive decline) emerge.

5.4 Connection to Volume III: Iron and Lipid Peroxidation

The third connection runs forward to the iron and GPX4 axis examined in Volume III. NAD+ is the upstream substrate from which NADPH is generated through the NAD+ kinase reaction; NADPH is the reducing equivalent that the glutathione reductase enzyme requires to regenerate reduced glutathione (GSH) from its oxidized form (GSSG); GSH is the substrate that GPX4 consumes to neutralize phospholipid hydroperoxides; and GPX4 activity is the principal defense against the iron-catalyzed lipid peroxidation that drives ferroptotic cell death. NAD+ depletion therefore propagates forward as NADPH depletion, GSH depletion, GPX4 substrate-limitation, and ferroptotic vulnerability. Restoring NAD+ restores the entire downstream cascade. The implication is that NAD+ restoration is not merely a bioenergetic intervention but also an antioxidant intervention — a duality that explains the broad geroneuroprotective profile of NAD+-restoring strategies and the mechanistic complementarity with the GPX4-stabilizing strategies examined in Volume III.

5.5 The Four-Component Regimen

The composite picture that emerges from Volumes I–III of this series is a coordinated four-component pharmacological regimen for age-associated neurodegeneration:

(i) a direct mitochondrial-function modulator (J-147 class, Volume I) that engages the AMPK-mTORC1 adaptive signaling program;
(ii) an upstream oxidative-damage suppressor (AG18051-class NQO2 inhibition, Volume I) that protects the bioenergetic machinery;
(iii) an NAD+ precursor (NR or NMN) paired with a CD38 inhibitor (78c-class or MK-class, Volume II) that restores the substrate supply to the entire OXPHOS-sirtuin-biogenesis system;
(iv) an iron-compartmentalizing chelator and/or a GPX4 stabilizer (Volume III) that arrests the lipid-peroxidation arm of the ferroptotic-bioenergetic spiral.

This regimen is the pharmacological analog of what cardiovascular medicine constructed across the second half of the twentieth century: not a single magic bullet but a coordinated multi-component intervention whose effects compose multiplicatively against the convergent failure modes of the aging system. The argument advanced here, and continued through Volume III, is that geroneuroprotection will follow the same trajectory.

Chapter VI — Translation, Combination Paradigms, and Predictions

6.1 The Current Clinical Landscape

The clinical-development landscape for NAD+ pharmacology in neurodegeneration is currently dominated by three programs. The ChromaDex Niagen (NR) program has completed Phase I and II trials in healthy aging, mild cognitive impairment, Parkinson's disease (NADPARK), and ALS, with the NADPARK trial as the methodologically strongest. The MetroBiotech (NMN) program has completed Phase I trials in healthy adults and is planning Phase IIa trials in MCI and age-related cognitive decline. The Merck (MK-class CD38 inhibitor) program has completed Phase I metabolic-disease trials and is planning a Phase II trial in MCI for 2026–2027.

No clinical trial has yet tested the combination of an NAD+ precursor with a CD38 inhibitor in a neurodegeneration indication. This is the single most consequential gap in the current clinical-development landscape, in the analyst's view. The mechanistic case for combination is overdetermined; the preclinical data is supportive; the regulatory path for combination trials of two well-characterized agents is tractable; and the clinical-development cost is modest relative to the potential benefit. The recommendation advanced in this monograph is that the combination trial be prioritized at the earliest practicable date.

6.2 Why Early Trials Underwhelmed

The disappointing results of first-generation NAD+ precursor trials in neurodegeneration have prompted significant field-level reflection. Four contributing factors are, in this analyst's view, principal: (i) precursor monotherapy fails to address the CD38 consumption arm; (ii) trial populations have established disease stages at which substrate supply is only one of several rate-limiting variables; (iii) trial durations (typically 30 days to 6 months) are inadequate to detect disease-trajectory modification; and (iv) trial endpoints have not been well matched to the upstream mechanism of action of the intervention. Each of these factors is addressable in next-generation trial design.

6.3 The Combinatorial Regimen

The case for combinatorial therapy in the NAD+ axis was advanced in §5.5 in the context of the four-component bioenergetic regimen. Within the NAD+ axis specifically, the foundational combination is an NAD+ precursor (NR or NMN, 250–1000 mg/day in current trial protocols) with a selective CD38 inhibitor (MK-class compound at the dose producing 70–90% CD38 suppression). The trial design should use a 24-month treatment period with primary endpoints of cerebrospinal-fluid NAD+ and NAD+ metabolite concentrations, secondary endpoints of FDG-PET hippocampal metabolic rate and cognitive performance, and exploratory endpoints of inflammatory cytokine panels and microglial-activation imaging markers. The population should be enriched for early-stage disease — preferably amnestic mild cognitive impairment with positive amyloid PET — and should incorporate a stratification by baseline microglial-activation status to distinguish responders from non-responders.

6.4 Falsifiable Predictions

Seven predictions follow from the analysis developed above, each operationalizable in extant experimental or clinical systems.

Prediction 1 (CD38 dominance). Conditional knockout of CD38 in forebrain microglia of aged APP/PS1 mice will produce a larger restoration of cortical NAD+ concentration than chronic NMN supplementation, and the combination of CD38 microglial knockout with NMN will produce an additive or supraadditive elevation. The prediction follows from the supply-and- demand reframing developed in Chapters I–III and would distinguish the consumption-dominance hypothesis from the synthesis-deficit alternative.

Prediction 2 (Combination synergy in trial). In a 24-month randomized controlled trial of NMN, MK-class CD38 inhibitor, and the combination in amnestic MCI, the combination arm will demonstrate cognitive-trajectory benefit superior to either monotherapy with a magnitude of synergy proportional to baseline CD38 expression measured in peripheral blood mononuclear cells. The prediction operationalizes the hose-and-bucket mechanism as a clinical hypothesis and provides a biomarker-based stratification strategy.

Prediction 3 (Microglial homeostasis rescue). Combination NAD+ precursor with CD38 inhibitor administration to aged or AD-model mice will produce restoration of the microglial homeostatic signature (TGFβ- dependent transcriptional program, P2RY12, TMEM119, SALL1 expression) exceeding either monotherapy. The prediction links the NAD+ axis to the Homeostatic Microglial Collapse framework of the ONS series.

Prediction 4 (SIRT3 deacetylation as biomarker). The acetylation status of SIRT3 substrates — particularly the mitochondrial superoxide dismutase SOD2 K68 and the F₁ ATP synthase α-subunit lysine sites — will serve as a leading pharmacodynamic biomarker of NAD+ pharmacology clinical benefit. The prediction operationalizes the SIRT3-ATP synthase connection developed in §5.2 and provides a route to dose-individualization.

Prediction 5 (J-147 + NAD+ combination). Co-administration of J-147 (Volume I) with the combination of NMN and CD38 inhibitor (Volume II) will produce ATP synthase functional restoration in aged neurons exceeding either intervention alone, with the magnitude of synergy proportional to baseline mitochondrial deacetylation status. The prediction operationalizes the Volume I/II combination as a clinical hypothesis.

Prediction 6 (PARP1 inhibitor adjunct). In conditions of high DNA damage burden (post-traumatic, ischemic, or accelerated-aging models), a PARP1 inhibitor added to the NAD+ precursor/CD38 inhibitor combination will produce additional cognitive and biomarker benefit. The prediction extends the consumption-dominance hypothesis to acute-stress contexts where PARP1 hyperactivation is the dominant NAD+ consumer.

Prediction 7 (Eicosanoid signature). The principal off-target effect of combination NAD+ therapy — to be monitored as a tolerability biomarker — will be alteration in cyclic ADP-ribose-dependent calcium mobilization, detectable as a small change in eicosanoid metabolite panels. The prediction operationalizes the cADPR concern raised in §3.8 as a clinical safety hypothesis.

Chapter VII — Conclusion

7.1 The Argument in Brief

The argument of this monograph reduces to seven propositions.

First, the age-related decline in NAD+ is among the most rigorously documented metabolic changes in the aging brain and is mechanistically upstream of mitochondrial dysfunction, sirtuin-program failure, and PARP-mediated DNA repair decline. Second, the decline reflects the integrated effect of falling synthesis, falling cellular import, and rising consumption — of which the CD38-mediated consumption arm has emerged in the last decade as the dominant variable. Third, the substrate-restoration strategy (NR, NMN, NAMPT activators) and the drain-arrest strategy (CD38 inhibition with 78c, MK-class, or flavonoid compounds) are mechanistically complementary and pharmacologically combinable. Fourth, the disappointing clinical record of first- generation NAD+ precursor trials in neurodegeneration reflects in part the failure to address the consumption arm — a failure addressable by combination therapy. Fifth, the NAD+ axis is mechanistically linked through SIRT3 deacetylation, PGC-1α-mediated biogenesis, and NADPH- GSH-GPX4 regeneration to the ATP synthase axis (Volume I) and the iron-GPX4 axis (Volume III), positioning the NAD+ precursor/CD38 inhibitor combination as the second component of a coordinated four- component bioenergetic regimen. Sixth, within the Collapse Trilogy framework, the NAD+ axis intersects most consequentially with the microglial homeostatic signature; the supply-and-demand reframing of NAD+ restoration is also a reframing of microglial homeostasis restoration. Seventh, the framework generates seven falsifiable predictions that operationalize the consumption-dominance hypothesis and the combination-therapy hypothesis as testable empirical claims.

7.2 What the Monograph Does Not Claim

The monograph does not claim that NAD+ restoration alone will produce disease-modification in established Alzheimer's or Parkinson's disease; the larger framework of the Collapse Trilogy and the Bioenergetic Pharmacology series is explicitly multi-component. It does not claim that NR is superior to NMN or that NMN is superior to NR; the available evidence does not yet support a confident comparative judgment. It does not claim that CD38 inhibition is the only consumption-arm intervention worth pursuing — PARP1 inhibition has a complementary role under high-DNA-damage conditions, and NAMPT activation is a generative next-frontier strategy. And it does not claim that the four-component regimen described in §5.5 is complete; the larger Collapse Trilogy framework points toward additional interventions at the circuit and synaptic levels that are not addressed in the bioenergetic-pharmacology series.

7.3 The Broader Significance

The broader significance of the NAD+ precursor/CD38 inhibitor combination is that it operationalizes, in the second domain of bioenergetic pharmacology, the same combinatorial logic that the ATP synthase modulator/NQO2 inhibitor combination operationalized in the first. The emerging pharmacology of geroneuroprotection is not a search for a single magic bullet but a construction of a coordinated multi-component regimen whose effects compose multiplicatively against the convergent failure modes of the aging brain. The NAD+ pool is the substrate supply on which every downstream catalytic machine — Complex I, ATP synthase, the sirtuins, the PARPs, the biogenic transcription factors — depends. Its restoration is the second foundational layer of the coordinated intervention. The pharmacology that operationalizes this restoration — through precursor supplementation, CD38 inhibition, and ultimately NAMPT activation — is the work of the next decade.

References

Bieganowski, P., & Brenner, C. (2004). Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell, 117(4), 495–502.

Brakedal, B., Dölle, C., Riemer, F., Ma, Y., Nido, G. S., Skeie, G. O., Craven, A. R., Schwarzlmüller, T., Brekke, N., Diab, J., Sverkeli, L., Skjeie, V., Varhaug, K., Tysnes, O. B., Peng, S., Haugarvoll, K., Ziegler, M., Grüner, R., Eidelberg, D., & Tzoulis, C. (2022). The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell Metabolism, 34(3), 396–407.

Camacho-Pereira, J., Tarragó, M. G., Chini, C. C. S., Nin, V., Escande, C., Warner, G. M., Puranik, A. S., Schoon, R. A., Reid, J. M., Galina, A., & Chini, E. N. (2016). CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metabolism, 23(6), 1127–1139.

Cerutti, R., Pirinen, E., Lamperti, C., Marchet, S., Sauve, A. A., Li, W., Leoni, V., Schon, E. A., Dantzer, F., Auwerx, J., Viscomi, C., & Zeviani, M. (2014). NAD+-dependent activation of Sirt1 corrects the phenotype in a mouse model of mitochondrial disease. Cell Metabolism, 19(6), 1042–1049.

Escande, C., Nin, V., Price, N. L., Capellini, V., Gomes, A. P., Barbosa, M. T., O'Neil, L., White, T. A., Sinclair, D. A., & Chini, E. N. (2013). Flavonoid apigenin is an inhibitor of the NAD+ase CD38: Implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes, 62(4), 1084–1093.

Fang, E. F., Scheibye-Knudsen, M., Brace, L. E., Kassahun, H., SenGupta, T., Nilsen, H., Mitchell, J. R., Croteau, D. L., & Bohr, V. A. (2014). Defective mitophagy in XPA via PARP-1 hyperactivation and NAD+/SIRT1 reduction. Cell, 157(4), 882–896.

Fang, E. F., Hou, Y., Palikaras, K., Adriaanse, B. A., Kerr, J. S., Yang, B., Lautrup, S., Hasan-Olive, M. M., Caponio, D., Dan, X., Rocktäschel, P., Croteau, D. L., Akbari, M., Greig, N. H., Fladby, T., Nilsen, H., Cader, M. Z., Mattson, M. P., Tavernarakis, N., & Bohr, V. A. (2019). Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer's disease. Nature Neuroscience, 22(3), 401–412.

Grozio, A., Mills, K. F., Yoshino, J., Bruzzone, S., Sociali, G., Tokizane, K., Lei, H. C., Cunningham, R., Sasaki, Y., Migaud, M. E., & Imai, S. I. (2019). Slc12a8 is a nicotinamide mononucleotide transporter. Nature Metabolism, 1(1), 47–57.

Hou, Y., Lautrup, S., Cordonnier, S., Wang, Y., Croteau, D. L., Zavala, E., Zhang, Y., Moritoh, K., O'Connell, J. F., Baptiste, B. A., Stevnsner, T. V., Mattson, M. P., & Bohr, V. A. (2018). NAD+ supplementation normalizes key Alzheimer's features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency. Proceedings of the National Academy of Sciences, 115(8), E1876–E1885.

Howard, M., Grimaldi, J. C., Bazan, J. F., Lund, F. E., Santos-Argumedo, L., Parkhouse, R. M. E., Walseth, T. F., & Lee, H. C. (1993). Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. Science, 262(5136), 1056–1059.

Lautrup, S., Sinclair, D. A., Mattson, M. P., & Fang, E. F. (2019). NAD+ in brain aging and neurodegenerative disorders. Cell Metabolism, 30(4), 630–655.

Luongo, T. S., Eller, J. M., Lu, M. J., Niere, M., Raith, F., Perry, C., Bornstein, M. R., Oliphint, P., Wang, L., McReynolds, M. R., Migaud, M. E., Rabinowitz, J. D., Johnson, F. B., Johnsson, K., Ziegler, M., Cambronne, X. A., & Baur, J. A. (2020). SLC25A51 is a mammalian mitochondrial NAD+ transporter. Nature, 588(7836), 174–179.

Massudi, H., Grant, R., Braidy, N., Guest, J., Farnsworth, B., & Guillemin, G. J. (2012). Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLOS ONE, 7(7), e42357.

Schmidt, M. S., & Brenner, C. (2019). Absence of evidence that Slc12a8 encodes a nicotinamide mononucleotide transporter. Nature Metabolism, 1(7), 660–661.

Tarragó, M. G., Chini, C. C. S., Kanamori, K. S., Warner, G. M., Caride, A., de Oliveira, G. C., Rud, M., Samani, A., Hein, K. Z., Huang, R., Jurk, D., Cho, D. S., Boslett, J. J., Miller, J. D., Zweier, J. L., Passos, J. F., Doles, J. D., Becherer, D. J., & Chini, E. N. (2018). A potent and specific CD38 inhibitor ameliorates age-related metabolic dysfunction by reversing tissue NAD+ decline. Cell Metabolism, 27(5), 1081–1095.

Trammell, S. A. J., Schmidt, M. S., Weidemann, B. J., Redpath, P., Jaksch, F., Dellinger, R. W., Li, Z., Abel, E. D., Migaud, M. E., & Brenner, C. (2016). Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nature Communications, 7, 12948.

Yamamoto, T., Byun, J., Zhai, P., Ikeda, Y., Oka, S., & Sadoshima, J. (2020). Nicotinamide mononucleotide, an intermediate of NAD+ synthesis, protects the heart from ischemia and reperfusion. PLOS ONE, 9(6), e98972.

Yoshida, M., Satoh, A., Lin, J. B., Mills, K. F., Sasaki, Y., Rensing, N., Wong, M., Apte, R. S., & Imai, S. I. (2019). Extracellular vesicle-contained eNAMPT delays aging and extends lifespan in mice. Cell Metabolism, 30(2), 329–342.

Zhu, X. H., Lu, M., Lee, B. Y., Ugurbil, K., & Chen, W. (2015). In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences. Proceedings of the National Academy of Sciences, 112(9), 2876–2881.

Note on Sources